Modular Antibody Technology
Our robust discovery engine lets us easily “mix-and-match” antibody components to create unique bispecific antibody products.
F-star develops genuine monoclonal bispecific antibodies that can bind two different targets at the same time, for use as “2-in-1” drugs.
News & Events
- 2 November 2015: F-star Appoints Dr Neil Brewis as Chief Scientific Officer
- 1 November 2015: F-star publication in Nature Biopharma Dealmarkers
- 5 October 2015: FS102 Preclinical Data Publication in Molecular Therapy